Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
Tongji Hospital · Huazhong University of Science and Technology · +4 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
475
total citations
- FWCI
- 11.57
- Percentile
- 100%
- References
- 38
Citations per year
Authors
21- YCYang Cao
Tongji Hospital, Huazhong University of Science and Technology
- JWJia Wei
Tongji Hospital, Huazhong University of Science and Technology
- LZLiang Zou
Wuhan No.1 Hospital
- TJTiebin Jiang
Central South University, Third Xiangya Hospital
- GWGaoxiang Wang
Tongji Hospital, Huazhong University of Science and Technology
Topics & keywords
Topics
Keywords
- Ruxolitinib
- Medicine
- Internal medicine
- Clinical trial
- Randomized controlled trial
- Placebo
- Surgery
- Pathology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.